Novel Deconvoluted Synchronous Spectrofluorimetric Method For Simultaneous Determination Of Bisoprolol and Atorvastatin As Single or Co-administrated Drugs in Bulk and Plasma; Green Assessment

A Dual-Mode Spectrophotometric and Fluorescent Probe Based on Lignin-Derived Carbon Dots for the Detection of Atorvastatin Calcium in a Bulk Powder and a Commercial Product

Recently, dual-mode techniques have garnered considerable attention and have been shown to be effective approaches for biomedical analysis and environmental monitoring. A novel and simple dual-mode spectrophotometric and fluorometric probe based on lignin-derived carbon dots (LCDs) was developed to detect atorvastatin calcium (ATS) in a bulk powder and its commercial product. The synthesized LCDs exhibit exceptional fluorescence characteristics and are highly soluble in water while maintaining reasonable stability. The average particle size of the LCDs was 3.42 ± 1.03 nm. The characterization of the produced LCDs indicated a structure resembling graphene oxide with the presence of several functional groups. The developed LCDs show a good fluorescence quantum yield of 32.2%. The fluorescence of the LCDs is quenched by ATS at an emission wavelength of 315 nm after excitation at 275 nm through dynamic and static quenching mechanisms. The optimal reaction conditions for the dual-mode reaction were a pH of 9 and 0.05 mL of the LCDs, which were measured after 3 min at 30 °C by spectrophotometry, followed by 7 min at 20 °C by fluorometric methods. According to the spectrophotometric results, the response of ATS was linear in the range of 4.0-100.0 µg/mL, while according to the fluorometric results, the dynamic range was 3.0-50.0 µg/mL. The limits of detection (LODs) and the limits of quantification (LOQs) were 0.97 µg/mL and 2.95 µg/mL for the fluorometric method, respectively. The nanoprobe effectively analyzed ATS in medication samples and yielded good results.

Eco-friendly novel deconvoluted synchronous spectrofluorimetric approach for the determination of favipiravir, levodropropizine and moxifloxacin hydrochloride as an effective therapeutic combination for COVID-19; application in laboratory prepared mixtures and spiked human plasma

In this work, a green, fast, and simple synchronous spectrofluorimetric approach has been developed to simultaneously determine favipiravir, levodropropizine, and moxifloxacin hydrochloride as co-administered medications for COVID-19 treatment in pure form and spiked human plasma. The synchronous fluorescence spectroscopy technique to analyze the studied drugs at Δλ = 110 nm enabled the determination of levodropropizine at 360 nm. Then, applying Fourier Self-Deconvolution to each spectra to measure favipiravir and moxifloxacin hydrochloride at peak amplitudes of 431 nm and 479 nm, respectively, without any interference. Favipiravir, levodropropizine, and moxifloxacin hydrochloride could be sensitively determined using the described approach over concentration ranges of 20-300 ng/mL, 10-600 ng/mL, and 50-500 ng/mL, respectively. The method's validation was carried out effectively in accordance with guidelines recommended by the ICH. Finally, the Eco-scale and Green Analytical Procedure Index (GAPI) techniques have been used to evaluate the greenness of the proposed method.

LC-MS/MS bioanalytical method for the quantitative analysis of nifedipine, bisoprolol, and captopril in human plasma: Application to pharmacokinetic studies

In this study, the development and validation of an accurate and highly sensitive LC-MS/MS method were performed for the estimation of nifedipine, bisoprolol and captopril in real human plasma. Liquid-liquid extraction using tert-butyl methyl ether was efficiently applied for extraction of the analytes from plasma samples. The chromatographic separation was carried out using an isocratic elution mode on the X-terra MS C18 column (4.6 × 50 mm, 3.5 μm). The mobile phase consisted of methanol-0.1% formic acid (95:5, v/v) for determination of nifedipine and bisoprolol and acetonitrile-0.1% formic acid (70:30, v/v) for determination of captopril with a flow rate of 0.5 ml/min. Acceptable results regarding the different validation characteristics of the analytes were obtained in accordance with US Food and Drug Administration recommendations for bioanalytical methods. The developed approach was linear over concentration ranges of 0.5-130.0, 50.0-4,500.0 and 0.3-30.0 ng/ml for nifedipine, captopril and bisoprolol, respectively. The method revealed a sufficient lower limit of quantification in the range of 0.3-50.0 ng/ml, as well as high recovery percentages, indicating high bioanalytical applicability. The proposed method was efficiently applied to a pharmacokinetic evaluation of a fixed-dose combination of the analytes in healthy male volunteers.